Thoraxonkologische Studien

ABP 2019

Titel: Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK*NSCLC) patients by deep phenotyping

Indikation: ALK, NSCLC

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2019-001828-36


ANTELOPE

Titel: Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF1 negative lung adenocarcinoma

Indikation: NSCLC

Patienteneinschluss: rekrutierend

EudraCT-Nummer: 2023-505054-17-00


AVANZAR

Titel: A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Indikation: NSCLC

Patienteneinschluss: rekrutierend

EudraCT-Nummer: 2021-004606-21

Weitere Informationen zur Studie auf www.clinicaltrialsregister.eu


BMS CA 209-73L

Titel: Nivolumab + Chemoradiotherapie (CCRT) gefolgt von Nivolumab und Ipilimumab oder Nivolumab + CCRT gefolgt von Nivolumab alleine vs. CCRT gefolgt von Durvalumab bei Patienten mit unbehandeltem, inoperablem und lokal fortgeschrittenem NSCLC

Indikation: NSCLC

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2019-001222-98

Weitere Informationen zur Studie auf www.clinicaltrials.gov


BMS CA 209 9 LA

Titel: A Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

Indikation: NSCLC

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2017-001195-35

Weitere Informationen zur Studie auf www.clinicaltrials.gov


BO 42592

Titel: A phase II, randomized, double-blind, placebo-controlled study of Tiragolumab in combination with Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab plus Pemetrexed and Carboplatin/Cisplatin in patients with previously untreated advanced non-squamous NSCLC

Indikation: NSCLC

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2020-002851-39

Weitere Informationen zur Studie auf www.clinicaltrials.gov


BO 42777

Titel: A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER

Indikation:  NSCLC

Patienteneinschluss:  rekrutierend

EudraCT-Nummer:  2021-004149-19

Weitere Informationen zur Studie auf www.clinicaltrialsregister.eu


BO 42863

Titel: A Phase 1/2 Study of the Highly-selective REF Inhibitor, Blue 667, in patients with Thyroid Cancer, NSCLC and other advanced solid tumors

Indikation: Thyroid Cancer, NSCLC, other advanced solid tumors

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2016-004390-41

Weitere Informationen zur Studie auf www.clinicaltrials.gov


BO45217

Titel: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB VERSUS SOTORASIB OR ADAGRASIB IN PATIENTS WITH PREVIOUSLY TREATED KRAS G12C-POSITIVE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Indikation: NSCLC

Patienteneinschluss: rekrutierend

EudraCT-Nummer: 2024-510908-37-00

Weitere Informationen zur Studie auf clinicaltrials.gov


CANOPY- A

Titel: A phase III, multicenter, randomized, double blind, placebocontrolled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)

Indikation: NSCLC

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2017-004011-39

Weitere Informationen zur Studie auf www.clinicaltrials.gov


CINC280I12201

Titel: A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1 ≥ 50%

Indikation: NSCLC

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2019-002660-27


Destiny Lung 04

Titel: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations

Indikation: NSCLC

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2021-000634-33

Weitere Informationen zur Studie auf www.clinicaltrials.gov


eVOLVE-Lung 02

Titel: A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC).

Indikation: NSCLC

Patienteneinschluss: rekrutierend

EudraCT-Nummer: 2023-000056-38

Weitere Informationen zur Studie auf clinicaltrials.gov


GO41767

Titel: A phase III, randomized, double-blind, placebo-controlled Study of ATEZOLIZUMAB plus CARBOPLATIN and ETOPOSIDE with or without TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) in patients with untreated extensive-stage small cell lung cancer

Indikation: small cell lung cancer

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2019-003301-97

Weitere Informationen zur Studie auf www.clinicaltrials.gov


GO 43104 (SCLC)

Titel: A phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) following first-line induction therapy with carboplatin,etoposide and atezolizumab

Indikation: ES-SCLC

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2021-001930-20


Molecular Fingerprinting in Cancer Detection L4L

Titel: Molekulares Fingerprinting zur Krebserkennung: Evaluation feldaufgelöster Spektroskopie zur in-Vitro Diagnostik verschiedener Krebsentitäten

Indikation: NSCLC, COPD

Patienteneinschluss: rekrutierend

EudraCT-Nummer: n.a.


Mariposa 73841937NSC3003

Titel: A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus singe Agent Osimertinib versus Lazertinib als First-Line Treatment in patients with EGFR-Mutated locally Advance ord Metastatic Non-Small Cell Lung Cancer

Indikation: NSCLC

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2020-000743-31

Weitere Informationen zur Studie auf www.clinicaltrials.gov


MK 7684-A-002

Titel: A Phase II, multicenter, randomized study to compare the Eficacy and safety of MK-7684A or MK-7694A plus Docetaxel versus Docetaxel Monotherapy in the treatment of patients with metastatic NSCLC with progressive disease after treatment with a platin doublet chemotherapy and Immunotherapy

Indikation: NSCLC

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2020-004034-38

Weitere Informationen zur Studie auf www.clinicaltrials.gov


MK3475-598

Titel: A Phase III, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs
Pembrolizumab plus Placebo in Previously Untreated, Metastatic/Recurrent Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS > or = 50%)

Indikation: NSCLC

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2016-004364-20

Weitere Informationen zur Studie auf www.clinicaltrials.gov


MK 3475-587

Titel: A Multicenter, Open-label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial

Indikation: NSCLC

Patienteneinschluss: aktiv

EudraCT-Nummer: 2017-004417-42

Weitere Informationen zur Studie auf www.clinicaltrials.gov


MK 3475-671

Titel: Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)

Indikation: NSCLC

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2017-001832-21

Weitere Informationen zur Studie auf www.clinicaltrials.gov


MK 3475-D46 (Evoke 03)

Titel: An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell Lung Cancer

Indikation: NSCLC

Patienteneinschluss: rekrutierend

EudraCT-Nummer: 2022-000836-49

Weitere Informationen zur Studie auf clinicaltrials.gov                                                                                                                 


MSD V940 /mRNA-4157

Titel: A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer(INTerpath-002)

Indikation: NSCLC

Patienteneinschluss: rekrutierend

EudraCT Nummer: 2023-504923-20

Weitere Informationen zur Studie auf clinicaltrials.gov


MO 41552

Titel: RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE III STUDY OF ENTRECTINIB VERSUS CRIZOTINIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBORING ROS1 GENE REARRANGEMENTS WITH AND WITHOUT CENTRAL NERVOUS SYSTEM METASTASES

Indikation: NSCLC

Patienteneinschluss: rekrutierend

EudraCT-Nummer: 2019-003859-11

Weitere Informationen zur Studie auf clinicaltrials.gov


TAK-788-3001

Titel: A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFRExon 20 Insertion Mutation

Indikation: NSCLC

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2019-001845-42

Weitere Informationen zur Studie auf www.clinicaltrials.gov


Pacific8

Titel: Phase III, Randomised, Double‑blind, Placebo‑controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non‑small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum‑based Concurrent Chemoradiation Therapy

Indikation: NSCLC

Patienteneinschluss: rekrutierend

EudraCt-Nummer: 2021-004327-32

Weitere Informationen zur Studie auf clinicaltrials.gov


SAFFRON

Titel: Phase III study in EGFR mutated, MET Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib

Indikation: NSCLC

Patienteneinschluss: rekrutierend

EudraCt-Nummer: 2021-006374-24

Weitere Informationen zur Studie auf clinicaltrials.gov


TIGER MESO

Titel: TTFields in general routine clinical care in patients with pleural mesothelioma study

Indikation: Pleural Mesotheliom

Patienteneinschluss: rekrutierend

Project No.: NCT05538806

Weitere Informationen zur Studie auf clinicaltrials.gov

 

Pneumologische Studien

KIN001-2003 COVID 19

Titel: An 8-week double-blind, randomized, placebocontrolled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients

Indikation: SARS-CoV-2

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2020-005849-16


KIN1902-2001 Sarkoidose

Titel: A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis

Indikation: Sarkoidose

Patienteneinschluss: rekrutierend

EudraCt-Nummer: 2021-004794-31


PneuRX-Lungenemphysem-Register-Studie

Titel: Versorgungsanalyse der Lungen Volumenteilreduktion bei Patienten mit einer schwergradigen chronischen Bronchitis mit dominantem Emphysem (COPD)

Indikation: Emphysem, COPD

Patienteneinschluss: rekrutierend


IM027068

Titel: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

Indikation: IPF

Patienteneinschluss: rekrutierend

EudraCT-Nummer: 2023-503697-21


IM0271015

Titel: A multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with progressive pulmonary fibrosis (PPF).

Indikation: PPF

Patienteneinschluss: rekrutierend

EudraCT-Nummer: 2023-503699-25

Weitere Informationen zur Studie auf clinicaltrials.gov

 

Infektiologische Studien

KIN001-2003 COVID 19

Titel: An 8-week double-blind, randomized, placebocontrolled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients

Indikation: SARS-CoV-2

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2020-005849-16


Otsuka-Pass Thioridazin-Therapiestudie

Titel: A Multicentre, EU-wide, Non-Interventional Post-Authorisation Study to Assess the Safety and Usage of Delamanid in Routine Medical Practice in Multidrug-Resistant Tuberculosis Patients

Indikation: XDR-TB

Patienteneinschluss: Rekrutierung beendet

EudraCT-Nummer: 2010-022271-59


PCP-Pneumocystis

Titel: Etablierung neuer diagnostischer Verfahren zur Erkennung der Pneumocystis jirovecii Pneumonie

Indikation: Pneumocystis jirovecii Pneumonie

Patienteneinschluss: rekrutierend


RKI – virologische SARI-Surveillance (Pilotstudie)

Titel: Virologische Surveillance schwerer akuter respiratorischer Infektionen bei stationär
behandelten Patienten (SARI-Surveillance)

Indikation: akute respiratorische Erkrankung und stationäre Aufnahme

Patienteneinschluss: Rekrutierung beendet


RKI – virologische SARI-Surveillance (Multizentrische Studie)

Titel: Virologische Surveillance schwerer akuter respiratorischer Infektionen bei stationär
behandelten Patienten (SARI-Surveillance)

Indikation: akute respiratorische Erkrankung und stationäre Aufnahme

Patienteneinschluss: rekrutierend


TID-2

Titel: TID-2 Synopsis Studie: Sammlung von Blutproben für die Bewertung der analytischen Leistung von zwei neuen In-vitro-Testsystemen für die Tuberkulose- Diagnostik

Indikation: Tuberkulose

Patienteneinschluss: Rekrutierung beendet


TID 3_ RBAG-2023-01

Titel: Evaluation of the clinical performance of the enzyme-linked immunosorbent assay RIDASCREEN® TB and the immunochromatographic lateral flow assay RIDA®QUICK TB in human plasma samples

Indikation: Tuberkulose

Patienteneinschluss: Rekrutierung beendet

Project No.: 2016-0013


ERADICATE

Titel: Inhaled ColiFin® in adult bronchiectasis patients with new asymptomatic Pseudomonas aeruginosa infection an open-label, proof of concept – randomized controlled trial.

Indikation: New asymptomatic Pseudomonas aeruginosa infection

Patienteneinschluss: rekrutierend

EU-CT Nummer: 2023-509277-22-00

 

Stand November 2024